Italy Crispr And Cas Genes Market Size & Outlook
Italy crispr and cas genes market, 2018-2030 (US$M)
Related Markets
Italy crispr and cas genes market highlights
- The Italy crispr and cas genes market generated a revenue of USD 111.5 million in 2024 and is expected to reach USD 252.4 million by 2030.
- The Italy market is expected to grow at a CAGR of 14.8% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 111.5 million |
| Market revenue in 2030 | USD 252.4 million |
| Growth rate | 14.8% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, Italy accounted for 2.4% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 688.9 million by 2030.
Product was the largest segment with a revenue share of 89.69% in 2024. Horizon Databook has segmented the Italy crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Research collaborations and agreement models among international CRISPR providers and research institutes, as well as other biotech companies of Italy, is expected to drive the country’s CRISPR market.
This agreement is expected to support an integrated discovery service platform of Axim. As a result of the agreement, application of CRISPR technology is expected to expand development of highly customized cell-based assays.
In June 2017, Italy’s San Raffaele University and Research Hospital entered into a three-year research collaboration with Italia Therapeutics, Inc., a U.S.-based biotechnology company, to harness the latter’s CRISPR/Cas9 genome editing technology.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy crispr and cas genes market size, by product & service, 2018-2030 (US$M)
Italy CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
